Regulation of endothelial nitric oxide synthase in pathophysiological conditions.

Regulation of endothelial nitric oxide synthase in pathophysiological conditions. Cardiovasc Hematol Disord Drug Targets. 2011 Oct 26; Authors: Isenović E, Soskić S, Düngen HD, Dobutovic B, Elvis T, Simone I, Marche P Abstract The nitric oxide (NO) cascade and endothelial NO synthase (eNOS) are best known for their role in endothelium-mediated relaxation of vascular smooth muscle (VSM). NO generated by eNOS has been established as a key regulatory signaling molecule in the vasculature. The activities of eNOS are controlled by intracellular calcium/calmodulin (CaM) and by binding of the molecular chaperone heat-shock protein 90 (Hsp90). A number of studies have demonstrated a close association between insulin resistance (IR) and NO bioactivity. Some recent studies demonstrate that insulin signalling is essential for normal cardiovascular (CV) function and lack of it such as IR result in CV dysfunction and disease. A key step in the initiation and progression of atherosclerosis is a reduction in the bioactivity of endothelial cell-derived NO. Multiple changes in endothelial function and eNOS activity accompany the onset and development of Type 2 diabetes mellitus (T2DM) and contribute to the development of cardiovascular disease (CVD). This review focuses on recent findings about regulation of eNOS in pathophysiological conditions such are: IR, T2DM and CVD. PMID: 22044039 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Related Links:

Patients with Type 2 Diabetes Mellitus (T2DM) suffer from a higher incidence and severity of pulmonary infections. This is likely due to immune impairment and structural abnormalities caused by T2DM-induced oxidative stress (OS) and chronic inflammation. Modulation of the Renin Angiotensin System (RAS) through blockade of the actions of angiotensin II (AII), or inducing the protective pathway, has the potential to reduce these pathological pathways. The effects of Angiotensin 1–7 [A(1-7)] and NorLeu3-A(1-7) [NorLeu], ligands of the protective RAS, on the innate immune response were evaluated in the db/db mouse model ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
CONCLUSIONS Silicone oil endotamponade in PPV was associated with an increased risk of IOP at 24-month follow-up. PMID: 31811816 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 9 December 2019Source: Journal of Functional FoodsAuthor(s): Milkica Grabež, Ranko Škrbić, Miloš P. Stojiljković, Vesna Rudić-Grujić, Marija Paunović, Aleksandra Arsić, Snježana Petrović, Vesna Vučić, Bosa Mirjanić-Azarić, Katarina Šavikin, Nebojša Menković, Teodora Janković, Nađa VasiljevićAbstractPomegranate peel contains high levels of various phytochemicals. We evaluated the effects of pomegranate peel extract (PoPEx) consumption on plasma lipid profile, fatty acids (FA) level and blood pressure (BP) in patients with diabetes mellitus type ...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Publication date: Available online 9 December 2019Source: Canadian Journal of DiabetesAuthor(s): Lingning Huang, Yongze Zhang, Yunmin Wang, Ximei Shen, Sunjie YanAbstractAimsInvestigate association between diabetic peripheral neuropathy (DPN)and above normal blood pressure in non-hypertensive patients with type 2 diabetes mellitus(T2DM). Compare the achievement of clinical target for DPN and non-DPN withT2DM .MethodsA retrospective survey was administered to 3810 patients with type 2 diabetes. Cases were grouped according to the Toronto Clinical Scoring System (TCSS): Non-DPN, Mild DPN, Moderate DPN and Severe DPN. 1835 pa...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Condition:   Diabetes Mellitus, Type 2 Interventions:   Dietary Supplement: BPL-1 Probiotic capsules;   Dietary Supplement: Placebo Sponsor:   Mónica Marazuela Azpíroz Completed
Source: - Category: Research Source Type: clinical trials
Conditions:   Type 2 Diabetes;   Gestational Diabetes Intervention:   Other: Observational Sponsors:   Universiti Putra Malaysia;   Ministry of Health, Malaysia;   Universiti Teknologi Mara Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Gestational diabetes mellitus (GDM) has serious effects on both mother and child. Like Type 2 Diabetes Mellitus, it is increasing in prevalence world-wide. In addition to obesity, sleep duration has been named...
Source: BMC Pregnancy and Childbirth - Category: OBGYN Authors: Tags: Research article Source Type: research
by Jan Menne, Eva Dumann, Hermann Haller, Bernhard M. W. Schmidt BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a positive effect on the progression of chronic kidney disease, but there is a concern that they might cause acute kidney injury (AKI). Methods and findingsWe conducted a systematic review and meta-analysis of the effect of SGLT2is on renal adverse events (AEs) in randomized controlled trials and controlled observational studies. PubMed, EMBASE, Cochrane library, and wer...
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research
AbstractCardiovascular diseases (CVD) are one of the leading causes of death worldwide. Testosterone (T) is an important sex hormone that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and quality of life in men. At the vascular level, the key effect of T is the vasorelaxation. This review discusses the molecular pathways and clinical implications of T in the vascular system. Firstly, the mechanisms involved in the T vasodilator effect will be presented. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, ...
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
AbstractBackgroundAlthough gastroparesis is seen in patients with type 2 diabetes mellitus (T2DM), the prevalence of symptoms suggestive of gastroparesis in patients with T2DM is unknown, particularly among African Americans.AimsTo determine the prevalence of symptoms associated with gastroparesis in a large community-based population of European Americans and African Americans with T2DM.MethodsIndividuals with T2DM in the Diabetes Heart Study were asked to complete the gastroparesis cardinal symptom index (GCSI) and other GI-related questionnaires. GCSI total score ≥ 18 represented moderate or worse symptoms sug...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Hematology | Insulin | Study